Handgrip strength asymmetry as a new biomarker for sarcopenia and individual sarcopenia signatures

Pratt, Jedd ORCID: https://orcid.org/0000-0002-7410-078X, Pessanha, Ludmilla, Narici, Marco, Boreham, Colin and De Vito, Giuseppe (2023) Handgrip strength asymmetry as a new biomarker for sarcopenia and individual sarcopenia signatures. Aging Clinical and Experimental Research, 35 (11). pp. 2563-2571. ISSN 1594-0667

Preview

Published Version Available under License Creative Commons Attribution. Download (839kB) | Preview

Abstract

Background: Although handgrip strength (HGS) asymmetry has clinical screening utility, its relevance to sarcopenia is unknown. This study examined the relationship between HGS asymmetry and sarcopenia signatures, and explored the relevance of circulating neural/neuromuscular markers. Methods: 9403 individuals aged 18–92 years participated in this study. Maximal HGS and skeletal muscle index (SMI) were determined using hand dynamometry and DXA. Sarcopenia was diagnosed upon the presence of low HGS and low SMI, according to cohort-specific thresholds. Plasma biomarkers were measured by ELISA in a sub-group of 269 participants aged 50–83 years. Asymmetry was determined as the highest recorded HGS divided by the highest recorded HGS of the opposite hand. Individuals with a ratio > 1.10 were classified as having asymmetrical HGS. Results: Subjects with asymmetrical HGS had significantly lower SMI (7.67 kg/m2 vs 7.71 kg/m2, p = 0.004) and lower HGS (37.82 kg vs 38.91 kg, p < 0.001) than those with symmetrical HGS. In those aged ≥ 50 years asymmetrical HGS was associated with 2.67 higher odds for sarcopenia [95% confidence interval: (CI) = 1.557–4.561, p < 0.001], 1.83 higher odds for low HGS only (CI 1.427–2.342, p < 0.001), and 1.79 higher odds for low SMI only (CI 1.257–2.554, p = 0.001). HGS asymmetry demonstrated acceptable diagnostic accuracy for sarcopenia (AUC = 0.727, CI 0.658–0.796, p < 0.001). Plasma neural cell adhesion molecule concentrations were 19.6% higher in individuals with asymmetrical HGS (185.40 ng/mL vs 155.00 ng/mL, p < 0.001) than those with symmetrical HGS. Discussion: Our findings demonstrate the utility of HGS asymmetry as a screening tool that may complement existing strategies seeking to combat sarcopenia. Biomarker analyses suggest that heightened denervation may be an important aetiological factor underpinning HGS asymmetry.